Anish Suri - Sep 23, 2021 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
PRESIDENT AND CSO
Signature
/s/ Anish Suri by Colin Sandercock, attorney-in-fact
Stock symbol
CUE
Transactions as of
Sep 23, 2021
Transactions value $
-$176,246
Form type
4
Date filed
9/27/2021, 04:30 PM
Next filing
Oct 8, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CUE Common Stock Options Exercise $128K +20K +26.72% $6.42 94.8K Sep 23, 2021 Direct F1
transaction CUE Common Stock Sale -$305K -20K -21.09% $15.23 74.8K Sep 23, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Options Exercise $0 -20K -13.79% $0.00 125K Sep 23, 2021 Common Stock 20K $6.42 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.58, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 The option vests in eight equal semi-annual installments beginning September 6, 2019.